Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial

Thorsten M. Leucker, William O. Osburn, Paula Reventun, Kimberley Smith, Brian Claggett, Bridget Anne Kirwan, Sophie de Brouwer, Marlene S. Williams, Gary Gerstenblith, David N. Hager, Michael B. Streiff, Scott D. Solomon, Charles J. Lowenstein

Research output: Contribution to journalArticlepeer-review

Abstract

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells. We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients with moderate COVID-19 were randomly assigned to receive either placebo or crizanlizumab, a P-selectin inhibitor, in a double-blind fashion. Crizanlizumab reduced P-selectin levels by 89%. Crizanlizumab increased D-dimer levels by 77% and decreased prothrombin fragment. There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19. (Crizanlizumab for Treating COVID-19 Vasculopathy [CRITICAL]; NCT04435184)

Original languageEnglish (US)
Pages (from-to)935-945
Number of pages11
JournalJACC: Basic to Translational Science
Volume6
Issue number12
DOIs
StatePublished - Dec 2021

Keywords

  • coronavirus
  • crizanlizumab
  • endothelial
  • exocytosis
  • inflammation
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial'. Together they form a unique fingerprint.

Cite this